The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the two currently FDA-approved CAR-T products for multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). He emphasizes that the choice between these treatments should be a collaborative decision between patient and doctor, focusing on optimizing the patient’s quality of life (QoL). Prof. Martin also highlights the potential for new CAR-T therapies in the future myeloma treatment landscape. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: BMS, Janssen, Sanofi Consultant: Pfizer, GSK
